product name Nutlin-3
References: Science. 2004 Feb 6;303(5659):844-8; Nature. 2006 Nov 2;444(7115):61-6.
581.5
Formula
C30H30Cl2N4O4
CAS No.
890090-75-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (171.9 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: 30 mg/mL (51.59 mM)
Solubility (In vivo)
Chemical Name
4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19415709
| Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. | |
|---|---|
| In Vivo | Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. |
| Animal model | Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells |
| Formulation & Dosage | Formulated in 2% Klucel, 0.5% Tween 80; 100 mg/kg; Oral BID |
| References | [1] Vassilev LT, et al. Science, 2004, 303(5659), 844-848. |
